登录    
  
首页 > 期刊论文 > 论文摘要
干细胞标志CD90与人肺腺癌A549细胞顺铂耐药之间的关系
         
The relationship between tumor stem cells marker CD90 and resistance to cisplatin in human lung adenocarcinoma A549 cells

摘    要
目的: 观察干细胞标志CD90与人肺腺癌A549细胞顺铂(cisplatin,CDDP)耐药性的关系,从耐药角度探讨CD90是否是肺癌干细胞的标志。方法: 应用成球实验、CCK-8(cell counting kit-8)和平板克隆形成实验检测549和A549/CDDP细胞的自我更新能力,FCM法检测A549和A549/CDDP贴壁细胞及细胞球中CD90+细胞的比例,细胞毒性实验检测CD90+A549和CD90-A549细胞对CDDP的耐药性。建立CD90+A549和CD90-A549细胞裸鼠移植瘤模型,检测体内CD90+A549细胞对CDDP的耐药性。结果: 与A549细胞比较,A549/CDDP细胞的成球能力、细胞增殖及克隆形成能力更强(P<0.01)。A549/CDDP贴壁细胞和细胞球中CD90+细胞比例分别高于A549贴壁细胞和细胞球(P<0.05)。CDDP作用CD90+A549细胞和CD90-A549细胞的IC50值分别为8.50和1.50μmol/L。经CDDP干预后,CD90+A549细胞裸鼠移植瘤体积大于CD90-A549细胞(P<0.05)。结论: A549/CDDP细胞具有较强的自我更新能力和较高比例的CD90+亚群细胞,CD90+A549细胞表现出较高的CDDP耐药性,提示CD90可能是肺癌的干细胞标志物。
标    签 肺肿瘤   肿瘤干细胞   顺铂   抗药性   肿瘤   CD90   A549细胞   Lung neoplasms   Neoplastic stem cells   Cisplatin   Drug resistance   neoplasm   CD90   A549 cells  
 
Abstract
Objective: To observe the relationship between stem cells marker CD90 and CDDP (cisplatin) resistance in lung adenocarcinoma A549 cells, and to explore whether CD90 is a marker of lung cancer stem cells. Methods: Self-renewal abilities of A549 and A549/CDDP cells were detected by sphere-forming assay, CCK-8 (cell counting kit-8) and plate colony-formation assay, respectively. The proportions of CD90+ in A549 cells, A549/CDDP adherent cells and the spheres cells were measured by FCM (flow cytometry). The CDDP resistance in CD90+ A549 cells and CD90-A549 cells was detected by cytotoxicity experiment. The CDDP resistance in CD90+ A549 cells in vivo was detected by using transplanted tumor in nude mice. Results: As compared with A549 cells, the abilities of sphere formation, proliferation and colony-formation efficiency of A549/CDDP cells were increased (P < 0.01). The proportions of CD90+ in A549/CDDP adherent cells and the sphere cells were higher than those in the corresponding A549 adherent cells and the sphere cells (P < 0.05). IC50 (half inhibitory concentration) values of CDDP in CD90+ A549 and CD90-A549 cells were 8.50 and 1.50 μmol/L, respectively. The tumor xenograft volume of CD90+ A549 cells was larger than that of CD90-A549 cells after treatment with CDDP in nude mice (P < 0.05). Conclusion: A549/CDDP cells show high self-renewal ability and CD90+ proportion. CD90+ A549 cells have high ability of CDDP resistance. CD90 may be a marker of lung cancer stem cells.

中图分类号 R734.2   DOI 10.3781/j.issn.1000-7431.2013.09.004

 
  购买该论文  中国光学期刊网论文下载说明
      


所属栏目 基础研究

基金项目 国家重点基础研究发展计划(973计划)(编号:2010CB529402)

收稿日期 2013/5/7

修改稿日期 2013/7/8

网络出版日期

作者单位点击查看


引用该论文: KUANG Li-shan,ZHOU Xiang-dong. The relationship between tumor stem cells marker CD90 and resistance to cisplatin in human lung adenocarcinoma A549 cells[J]. Tumor, 2013, 33(9): 770~775
况里杉,周向东. 干细胞标志CD90与人肺腺癌A549细胞顺铂耐药之间的关系[J]. 肿瘤, 2013, 33(9): 770~775


论文评价
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
分享论文
分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

参考文献
【1】McWILLIAMS A, LAM B, SUTEDJA T. Early proximal lung cancer diagnosis and treatment[J]. Eur Respir J, 2009, 33(3):656-665.
 
【2】BURSTEIN H J, MANGU P B, SOMERFIELD M R,et al. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays[J]. J Clin Oncol, 2011, 29(24):3328-3330.
 
【3】况里杉, 王宇亮, 周向东. 碱基切除修复与抗肿瘤药物耐药[J]. 肿瘤, 2013, 33(3):294-298.
 
【4】BAKER M. Cancer stem cells tracked[J]. Nature, 2012, 488(7409):13-14.
 
【5】GANGEMI R, PALEARI L, ORENGO A M, et al. Cancer stem cells:a new paradigm for understanding tumor growth and progression and drug resistance[J]. Curr Med Chem, 2009, 16(14):1688-1703.
 
【6】DEAN M, FOJO T, BATES S, Tumour stem cells and drug resistance[J]. Nat Rev Cancer, 2005, 5(4):275-284.
 
【7】WANG Y L, ZHU B J, QI Z Z, et al. Akt1 enhances CA916798 expression through mTOR pathway[J]. PloS one, 2013, 8(5):e62327.
 
【8】闫秀萍, 罗虎, 周向东. 人肺癌细胞系A549中肿瘤干细胞样细胞的分离及鉴定[J]. 第三军医大学学报, 2012, 34(12):1153-1157.
 
【9】赵斌, 葛金芳, 朱娟娟, 等. 小议在MTT法测细胞增殖抑制率中IC50的计算方法[J]. 安徽医药, 2007, 11(9):834-836
 
【10】JUNG M J, RHO J K, KIM Y M, et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells[J]. Oncogene, 2013, 32(2):209-221.
 
【11】LEVINA V, MARRANGONI A M, DeMARCO R, et al. Drug-selected human lung cancer stem cells:cytokine network, tumorigenic and metastatic properties[J]. PLoS One, 2008, 3(8):e3077.
 
【12】HOFFMEYER K, RAGGIOLI A, RUDLOFF S, et al. Wnt/β-catenin signaling regulates telomerase in stem cells and cancer cells[J]. Science, 2012, 336(6088):1549-1554.
 
【13】TENG Y, WANG X, WANG Y, et al. Wnt/betacatenin signaling regulates cancer stem cells in lung cancer A549 cells[J]. Biochem Biophys Res Commun, 2010, 392(3):373-379.
 
【14】JIANG F, QIU Q, KHANNA A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer[J]. Mol Cancer Res, 2009, 7(3):330-338.
 
【15】NIAN W Q, CHEN F L, AO X J, et al. CXCR4 positive cells from Lewis lung carcinoma cell line have cancer metastatic stem cell characteristics[J]. Mol Cell Biochem, 2011, 355(1-2):241-248.
 
【16】BERTOLINI G, ROZ L, PEREGO P, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment[J]. Proc Natl Acad Sci USA, 2009, 106(38):16281-16286.
 
【17】CUI F, WANG J, CHEN D, et al. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer[J]. Oncol Rep, 2011, 25(3):701-708.
 
【18】MENG X, LI M, WANG X, et al. Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells[J]. Cancer Sci, 2009, 100(6):1040-1046.
 
【19】TOMULEASA C, SORITAU O, RUS-CIUCA D, et al. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma[J]. J Gastrointestin Liver Dis, 2010, 19(1):61-67.
 
【20】TONG C M, MA S, GUAN X Y. Biology of hepatic cancer stem cells[J]. J Gastroenterol Hepatol, 2011, 26(8):1229-1237.
 
【21】YANG Z F, HO D W, NG M N, et al. Significance of CD90+ cancer stem cells in human liver cancer[J]. Cancer cell, 2008, 13(2):153-166.
 
【22】陈晋峰, 张力建, 赵爱莲, 等. Thy-1肿瘤标记物在肺癌组织中的异常表达及其对肺癌患者预后的影响[J]. 中华医学杂志, 2005, 85(27):1921-1925.
 
【23】高全立, 汪萍. 小细胞肺癌干细胞样细胞的分离鉴定[J]. 中国癌症杂志, 2010, 20(6):421-426.
 
【24】WANG P, GAO Q, SUO Z, et al. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines[J]. PLoS one, 2013, 8(3):e57020.
 
【25】PIROZZI G, TIRINO V, CAMERLINGO R, et al. Epithelial to mesenchymal transition by TGFbeta-1 induction increases stemness characteristics in primary non small cell lung cancer cell line[J]. PLoS one, 2011, 6(6):e21548.
 
【26】SALCIDO C D, LAROCHELLE A, TAYLOR B J, et al. Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer[J]. Br J Cancer, 2010, 102(11):1636-1644.
 
相关信息
   标题 相关频次
 碱基切除修复与抗肿瘤药物耐药
 7
 rhGM-CSF和rhG-CSF对A549细胞顺铂化疗敏感性的影响
 6
 长程多柔比星化疗富集乳腺肿瘤干细胞
 6
 核仁磷酸蛋白和c-Src在耐药肺腺癌细胞中的表达及其与化疗耐药之间的关系
 6
 吉非替尼耐药细胞株的筛选和基因谱表达研究
 6
 人肺腺癌吉非替尼耐药细胞株中微小RNA的表达谱
 6
 表皮生长因子受体信号通路与卵巢癌耐药细胞株SKOV3/DDP相关性的研究
 5
 蟾毒灵逆转肺腺癌H1975细胞对吉非替尼耐药的体内实验研究
 5
 红芪多糖1联合顺铂对肺癌A549细胞凋亡的协同作用及其机制探讨
 5
 人肺腺癌干细胞对顺铂和卡铂的药物敏感度分析
 5
 Livin基因反义寡核苷酸诱导肺腺癌A549细胞的凋亡
 4
 A549肺癌细胞球抗凋亡能力及耐药蛋白表达分析
 4
 BAG-1蛋白在衣霉素诱导人肺癌A549细胞内质网应激及提高顺铂敏感性中的作用
 4
 H2O2氧化刺激对紫杉醇耐药和敏感肺癌细胞的不同影响
 4
 Layilin的RNAi对透明质酸诱导人肺腺癌A549细胞体外增殖的影响
 4
 NVB+DDP联合化疗治疗晚期非小细胞肺癌
 4
 RNA干扰抑制Apollon表达联合川芎嗪可增强白血病细胞对化疗药物的敏感性
 4
 TSA对肺腺癌细胞株A549细胞凋亡的影响
 4
 低氧对人肺腺癌A549多细胞球体上皮-间质转化促转移的影响
 4
 凋亡肿瘤细胞致敏的树突状细胞疫苗治疗肺癌的实验研究
 4
 光动力治疗联合顺铂对顺铂耐药肺癌细胞的体外治疗效应
 4
 汉黄芩素对肺腺癌A549细胞黏附和迁移能力的影响及其可能机制
 4
 槲皮素联合顺铂对肺腺癌小鼠移植瘤Bcl-2和Bax表达的调控及意义
 4
 健择联合顺铂3周与4周方案治疗NSCLC的疗效比较
 4
 结直肠癌奥沙利铂耐药相关蛋白的筛选与鉴定
 4
 咖啡酸联合顺铂对肺腺癌A549细胞增殖与凋亡的影响
 4
 雷帕霉素对肺癌A549细胞球增殖和上皮-间质转化的作用研究
 4
 硫利达嗪联合顺铂抑制肺癌A549及A549/DDP细胞的增殖
 4
 缺氧对肺腺癌细胞HIF-1α、GLUT-1、MMP-2表达影响的研究
 4
 上皮-间质转化和胰岛素样生长因子Ⅰ型受体在非小细胞肺癌EGFR-TKIs获得性耐药中的作用
 4

  热点专题


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3
沪ICP备15036656号-2